Starpharma Holdings slumps on FDA denial for therapy product

Starpharma Holdings

19/02/2024 24:34

** Shares of Starpharma Holdings  SPL.AX  slump as much as
13.8% to A$0.125, set to see their worst day since Aug 1, if
losses hold 
    ** The pharmaceutical firm says the United States Food and
Drug Administration (USFDA) requires more clinical efficacy data
to approve co's bacterial vaginosis therapy product VivaGel BV 
    ** Adds that it does not plan to pursue additional clinical
studies for VivaGel BV at this time 
    ** Shares hit lowest since Dec 6 
    ** Stock has fallen ~14.7% this year, as of last close

    

 (Reporting by Archishma Iyer in Bengaluru)
 ((Archishma.Iyer@thomsonreuters.com;))